Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06071728 · ClinicalTrials.gov registry record · NA

Restoring Glycocalyx Thickness in Older Adults to Improve Vascular Function

A NA study, sponsored by University of Iowa.

Completed
Registry status
NA
Development phase
24
Enrollment target

NCT06071728: Completed NA study, sponsored by University of Iowa.

NCT06071728 is a NA study that has completed, run by University of Iowa. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06071728, a NA study, has completed, sponsored by University of Iowa.

COMPLETED
Registry status
NA
Development phase
24 participants
Enrollment target

Study Summary

The glycocalyx serves as the interface between flowing blood and endothelial cells, the single cell layer that lines blood vessels, and is crucial for normal blood vessel function. Specifically, the glycocalyx protects endothelial cells from oxidative stress and inflammation and enables blood vessel dilation, which is largely dependent on the bioavailability of the vasodilatory molecule nitric oxide. Importantly, glycocalyx thickness decreases with age and is predictive of major adverse cardiovascular events in older adults free of cardiovascular disease. Therefore, interventions aimed at restoring glycocalyx thickness in older adults are desperately needed. Endocalyx Pro is a commercially available glycocalyx precursor supplement, manufactured by Microvascular Health Solutions, designed to 1) repair a damaged glycocalyx, 2) protect against damage to the glycocalyx, and 3) synthesize new glycocalyx components, and has been used to increase glycocalyx thickness in humans. However, no study has tested if glycocalyx thickness restores glycocalyx thickness in older adults and improves blood vessel function. Thus, the purpose of this investigation is to determine if 12-weeks of Endocalyx Pro supplementation alters glycocalyx thickness and blood vessel function in older adults. The investigators will use a camera placed under the tongue to determine glycocalyx thickness. The investigators will measure blood vessel function by measuring brachial artery dilation with ultrasound and arterial stiffness using pressure probes placed on the carotid and femoral artery.

Primary Outcome

Conduit artery vascular endothelial function

Interventions

  • DIETARY_SUPPLEMENT Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572)

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2022-10-10
Est. Completion 2024-01-31
Phase NA
University of Iowa

228 total trials

What the finished NCT06071728 record still lists

NCT06071728 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572) is the first listed.

NCT06071728 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06071728 about?

NCT06071728 is a clinical study titled "Restoring Glycocalyx Thickness in Older Adults to Improve Vascular Function". The glycocalyx serves as the interface between flowing blood and endothelial cells, the single cell layer that lines blood vessels, and is crucial for normal blood vessel function. Specifically, the glycocalyx protects endothelial cells from oxidative stress and inflammation and enables blood vessel...

What is the current status of trial NCT06071728?

This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2022-10-10. Estimated completion is 2024-01-31.

What interventions are being tested in trial NCT06071728?

The interventions under investigation include: Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572) (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06071728?

This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06071728's enrollment target sits among peer trials

24 1736th of 2000 higher than 246 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06071728, the US trial registry maintained by the National Library of Medicine. NCT06071728 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.